Wikidata

(Q85001070)

English

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

scientific article published on 01 March 2012

In more languages

Statements

title
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs (English)
1 reference
stated in
Europe PubMed Central
PubMed ID
21952978
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21952978%20AND%20SRC:MED&resulttype=core&format=json
retrieved
13 February 2020
author name string

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q85001070&oldid=1509225298"